格隆匯APP獲悉,根據聯交所最新權益披露資料顯示,2022年1月7日,昭衍新藥(06127.HK)獲Aggregate of abrdn plc affiliated investment management entities在場內以每股均價54.0177港元增持24.68萬股,涉資約1333.2萬港元。
增持後,Aggregate of abrdn plc affiliated investment management entities最新持股數目為364.7萬股,持股比例由5.60%上升至6.01%。